Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [ ¹⁷⁷ Lu]Lu-PSMA-617.

Autor: Muniz M; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota; munizrincon.miguel@mayo.edu., Sartor O; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota., Orme JJ; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota., Koch RM; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Rosenow HR; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Mahmoud AM; Department of Radiation Oncology, Kansas University Medical Center, Kansas City, Kansas., Andrews JR; Department of Urology, Mayo Clinic, Phoenix, Arizona., Kase AM; Department of Medical Oncology, Mayo Clinic, Jacksonville, Florida., Riaz IB; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona., Belge Bilgin G; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota., Thorpe MP; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota., Kendi AT; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota., Johnson GB; Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota.; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Ravi P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and., Kwon ED; Department of Urology, Mayo Clinic, Rochester, Minnesota., Childs DS; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Autor: Orme JJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA., Taza F; Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA., De Sarkar N; Department of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA., Tewari AK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Arsalan Naqvi S; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA., Riaz IB; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA., Childs DS; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Omar N; Ascension St Agnes Hospital, Baltimore, MD, USA., Adra N; Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA., Ashkar R; Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA., Cheng HH; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA., Schweizer MT; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA., Sokolova AO; Oregon Health Sciences University, Portland, OR, USA., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Barata P; UH Seidman Cancer Center, Cleveland, OH, USA., Sartor O; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Bastos D; Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil., Smaletz O; Hospital Israelita Albert Einstein, São Paulo, Brazil., Berchuck JE; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., McClure H; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Aggarwal R; University of California San Francisco, San Francisco, CA, USA., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Vlachostergios PJ; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Alva AS; University of Michigan, Ann Arbor, MI, USA., Mehra N; Radboud University, Nijmegen, The Netherlands., Nelson PS; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA., Hwang J; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA., Dehm SM; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; Masonic Cancer Center, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; Department of Urology, University of Minnesota, Minneapolis, MN, USA., Shi Q; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Fleischmann Z; Foundation Medicine Inc, Cambridge, MA, USA., Sokol ES; Foundation Medicine Inc, Cambridge, MA, USA., Elliott A; Caris Life Sciences, Irving, TX, USA., Huang H; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA., Bryce A; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA., Marshall CH; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Antonarakis ES; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; Masonic Cancer Center, Minneapolis, MN, USA. Electronic address: anton401@umn.edu.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Aug; Vol. 7 (4), pp. 877-887. Date of Electronic Publication: 2023 Dec 09.

Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?

Autor: Ahmed ME; Department of Urology, Mayo Clinic, Rochester, MN, USA., Mahmoud AM; Department of Urology, Mayo Clinic, Rochester, MN, USA., Reitano G; Department of Urology, Mayo Clinic, Rochester, MN, USA., Zeina W; Department of Urology, Mayo Clinic, Rochester, MN, USA., Lehner K; Department of Urology, Mayo Clinic, Rochester, MN, USA., Day CA; Department of Urology, Mayo Clinic, Rochester, MN, USA., Riaz I; Department of Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA., Childs DS; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Orme JJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Tuba Kendi A; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA., Johnson GB; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA., Jeffrey Karnes R; Department of Urology, Mayo Clinic, Rochester, MN, USA., Kwon ED; Department of Urology, Mayo Clinic, Rochester, MN, USA., Andrews JR; Department of Urology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Publikováno v: European urology open science [Eur Urol Open Sci] 2024 Jun 26; Vol. 66, pp. 38-45. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.

Autor: Muniz M; Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: munizrincon.miguel@mayo.edu., Loprinzi CL; Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: cloprinzi@mayo.edu., Orme JJ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: orme.jacob@mayo.edu., Koch RM; Department of Internal Medicine, Mayo Clinic, Rochester, MN, US. Electronic address: koch.regina@mayo.edu., Mahmoud AM; Department of Urology, Mayo Clinic, Rochester, MN, US. Electronic address: mahmoud.ahmed@mayo.edu., Kase AM; Department of Medical Oncology, Mayo Clinic, Jacksonville FL, US. Electronic address: kase.adam@mayo.edu., Riaz IB; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, US. Electronic address: riaz.irbaz@mayo.edu., Andrews JR; Department of Urology, Mayo Clinic Arizona, Phoenix, AZ, US. Electronic address: andrews.jack@mayo.edu., Thorpe MP; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, US. Electronic address: thorpe.matthew@mayo.edu., Johnson GB; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, US; Department of Immunology, Mayo Clinic, Rochester, MN, US. Electronic address: johnson.geoffrey@mayo.edu., Kendi AT; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, US. Electronic address: kendi.ayse@mayo.edu., Kwon ED; Department of Urology, Mayo Clinic, Rochester, MN, US. Electronic address: kwon.eugene@mayo.edu., Nauseef JT; Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, US. Electronic address: jtn2001@med.cornell.edu., Morgans AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US. Electronic address: aliciak_morgans@dfci.harvard.edu., Sartor O; Department of Medical Oncology, Mayo Clinic, Rochester, MN, US; Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, US. Electronic address: sartor.oliver@mayo.edu., Childs DS; Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: childs.daniel@mayo.edu.

Publikováno v: Cancer treatment reviews [Cancer Treat Rev] 2024 Jun; Vol. 127, pp. 102748. Date of Electronic Publication: 2024 Apr 30.

Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy.

Autor: Muniz M; From the Division of Medical Oncology., Childs DS; From the Division of Medical Oncology., Orme JJ; From the Division of Medical Oncology., Johnson GB; Division of Nuclear Medicine, Department of Radiology and Department of Immunology, Mayo Clinic, Rochester, MN., Sartor O; From the Division of Medical Oncology.

Publikováno v: Clinical nuclear medicine [Clin Nucl Med] 2024 Apr 01; Vol. 49 (4), pp. e164-e165. Date of Electronic Publication: 2024 Feb 06.